[基于转录学和实验验证的Tongguan囊干预心力衰竭的机制]
Ya-Fang Tan1, Yu-Han Fu2, Min-Zhou Zhang1
1the Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou 510180, China.
概括
光囊 (TG) 改善心脏功能,并降低异二醇诱导的心力衰竭 (HF) 的老鼠心肌纤维化. TG治疗调节了细胞外矩阵重塑,为高频率患者提供了潜在的治疗益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 异二醇 (ISO) 注射是一种常见的方法来诱导心力衰竭 (HF) 在老鼠模型.
- 细胞外基质 (ECM) 改造在心肌纤维化和心肌纤维化进展中起着至关重要的作用.
- 瓜囊 (TG) 是一种具有潜在心脏保护性能的传统药物.
研究的目的:
- 为了研究TG对ISO诱导的HF在老鼠中的治疗作用.
- 阐明TG的心脏保护作用背后的分子机制,特别是其在ECM重塑中的作用.
- 使用转录基因分析预测HF治疗中关键的分子标和途径.
主要方法:
- 在老鼠中使用ISO注射诱导HF,然后用TG或captopril进行治疗.
- 评估心脏功能通过心声回声和生物化学标志物 (LDH,MDA,SOD) 的测量.
- 心脏组织的组织病理学分析 (HE,马森三色,西里乌斯红色染色) 和转录组分析以确定差异表达的基因.
- 使用qPCR和西方 blot.使用关键基因和蛋白质表达 (ColI,ColIII,MMP2,FN-1) 的验证.
主要成果:
- 在ISO诱导的HF大鼠中,TG治疗显著改善了心脏功能,降低了心脏重量指数,并调节了生化标志物.
- 组织学检查显示,TG可以缓解心肌损伤并减少原沉积.
- 转录组分析确定了ECM受体相互作用途径作为关键目标,TG降低了原1a1,原3a1和MMP2的表达.
- qPCR和西部斑块证实了TG对ColI,ColIII,MMP2和FN-1表达的抑制作用.
结论:
- 通关囊在老鼠中显示出显著的心脏保护作用,防止ISO诱导的心力衰竭.
- TG可以缓解心肌损伤,改善心脏功能,并通过调节ECM重塑来缓解病理变化.
- TG的机制涉及与ECM合成和降解相关的关键基因和蛋白质的调节,为HF提供了潜在的治疗策略.
相关概念视频
01:29Heart Failure II: Pathophysiology
704
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
704
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:30Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:17Pathophysiology of Heart Failure
2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K